Clinical association of circulating VEGF-B levels with hyperlipidemia and target organ damage in type 2 diabetic patients

Journal of Biological Regulators and Homeostatic Agents

Volumn 28, Issue 2, 2014, Pages 225-236

  Sun, C Y ^a   Lee, C C ^a   Hsieh, M F ^a   Chen, C H ^a   Chou, Kuei Mei ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Target organ damage; Type 2 diabetes mellitus; Vascular endothelial growth factor B

Indexed keywords

AGED; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; MALE; MIDDLE AGED; TRIGLYCERIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR B;

EID: 84905647730     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Smyth S, Heron A. Diabetes and obesity: the twin epidemics. Nat Med 2006; 12:75-80. (Pubitemid 43050080)
2. Campos C. Chronic hyperglycemia and glucose toxicity: pathology and clinical sequelae. Postgrad Med 2012; 124:90-97.
3. Welle S, Nair KS. Failure of glyburide and insulin treatment to decrease leucine flux in obese type II diabetic patients. Int J Obes 1990; 14:701-10. (Pubitemid 20261773)
4. Avramoglu RK, Qiu W, Adeli K. Mechanisms of metabolic dyslipidemia in insulin resistant states: deregulation of hepatic and intestinal lipoprotein secretion. Front Biosci 2003; 8:d464-d476. (Pubitemid 38943204)
5. Holmes DI, Zachary I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol 2005; 6:209.
6. Li X, Kumar A, Zhang F, Lee C, Tang Z. Complicated life, complicated VEGF-B. Trends Mol Med 2012; 18:119-127.
7. Li X, Aase K, Li H, von Euler G, Eriksson U. Isoformspecific expression of VEGF-B in normal tissues and tumors. Growth Factors 2001; 19:49-59. (Pubitemid 32970680)
8. Aase K, Lymboussaki A, Kaipainen A, Olofsson B, Alitalo K, Eriksson U. Localization of VEGF-B in the mouse embryo suggests a paracrine role of the growth factor in the developing vasculature. Dev Dyn 1999; 215:12-25. (Pubitemid 29215700)
9. Mould AW, Greco SA, Cahill MM, et al. Transgenic overexpression of vascular endothelial growth factor-B isoforms by endothelial cells potentiates postnatal vessel growth in vivo and in vitro. Circ Res 2005; 97:e60-e70.
10. Karpanen T, Bry M, Ollila HM, et al. Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res 2008; 103:1018-26.
11. Hagberg CE, Falkevall A, Wang X, et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 2010; 464:917-21.
12. Hagberg CE, Mehlem A, Falkevall A, et al. Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature 2012; 490:426-30.
13. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539-53. (Pubitemid 28319935)
14. Standards of Medical Care in Diabetes. Diab Care 2012; 35:11-63.
15. Hudson C. The clinical features and classification of diabetic retinopathy. Ophthalmic Physiol Opt 1996; 16:43-48.
16. Kanji JN, Anglin RE, Hunt DL, Panju A. Does this patient with diabetes have large-fiber peripheral neuropathy? JAMA 2010; 303:1526-32.
17. Gaylis H. Diagnosis and treatment of peripheral arterial disease. JAMA 2002; 287:313.
18. Bakker AJ. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 1999; 22:307-13. (Pubitemid 29056927)
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-19. (Pubitemid 15018832)
20. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85:2402-10. (Pubitemid 32269192)
21. Campbell DJ, Somaratne JB, Jenkins AJ, et al. Reduced microvascular density in non-ischemic myocardium of patients with recent non-ST-segment- elevation myocardial infarction. Int J Cardiol 2013; 167:1027-37.
22. Ripsin CM, Kang H, Urban RJ. Management of blood glucose in type 2 diabetes mellitus. Am Fam Physician 2009; 79:29-36.
23. Kacso IM, Bondor CI, Kacso G. Soluble serum Klotho in diabetic nephropathy: relationship to VEGF-A. Clin Biochem 2012; 45:1415-20.
24. Zhang X, Bao S, Hambly BD, Gillies MC. Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy. Int J Biochem Cell Biol 2009; 41:2368-71.
25. Tufro A, Veron D.VEGF and podocytes in diabetic nephropathy. Semin Nephrol 2012; 32:385-93.
26. Muoio DM. Metabolism and vascular fatty acid transport. N Engl J Med 2010; 363:291-93.
27. Gnudi L, Thomas SM, Viberti G. Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism. J Am Soc Nephrol 2007; 18:2226-32. (Pubitemid 47203836)
28. Zhong X, Huang H, Shen J, Zacchigna S, Zentilin L, Giacca M, Vinores SA. Vascular endothelial growth factor-B gene transfer exacerbates retinal and choroidal neovascularization and vasopermeability without promoting inflammation. Mol Vis 2011; 17:492-507.
29. Devaux Y, Vausort M, Azuaje F, et al. Low levels of vascular endothelial growth factor B predict left ventricular remodeling after acute myocardial infarction. J Card Fail 2012; 18:330-37.